Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-115 Alone or with Azacitidine in R/R AML, CMML, MDS
NCT04358393Phase 2
Key facts
- Status
- Recruiting
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Countries
- 1
- Sponsor
- Ascentage Pharma
- Modality
- Small Molecules
- Drugs
- alrizomadlin
- Conditions
- acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)myelodysplastic syndrome (MDS)
01
Overview
Phase 2, open-label trial of alrizomadlin in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Ascentage Pharma. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Dec 2020; status: recruiting.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
APG-115 Monotherapy
APG-115 alone
APG-115 + Azacitidine
APG-115 combined with Azacitidine
03
Who it enrols
Patients with relapsed or refractory AML, CMML, or high-risk MDS who have exhausted standard therapies, with adequate organ function and no active CNS leukemia or recent stem cell transplant.
04
Endpoints
Primary
Maximum Tolerated Dose
Beyond the preview
Go deeper on NCT04358393.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04358393.